Anemia in MDS (Myelodysplastic syndromes) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

A component of myelodysplastic syndromes (MDS) is refractory anemia. MDS is an acquired disease of the pluripotent stem cells that results in one or more peripheral leukopenias and dysplasia in the bone marrow and peripheral blood. Due to the patients' similar peripheral blood patterns, MDS and aplastic anemia are sometimes categorized as bone marrow failure disorders. Unknown is the actual incidence of MDS in the US. There are reportedly 1,500 new cases of MDS every year, which was the year it was first identified as a distinct disorder. Less than 5% of patients with the rash were believed to have the illness at the time. MDS was first recorded in cancer registries in 2001 despite not being categorized as a tumor. Some MDS patients who experience bothersome symptoms or low blood counts may not require immediate medical attention. In young, relatively healthy patients, stem cell transplantation (SCT) may be the treatment of choice if a suitable donor is available because it is frequently thought to be the only treatment option for MDS when it is necessary.

Description

MDS, or myelodysplastic syndromes, include refractory anemia. MDS is an acquired disease of the pluripotent stem cells that results in dysplasia of the bone marrow and one or more peripheral leukopenias. Due to the patients' similar peripheral blood patterns, bone marrow failure disorders such as MDS and aplastic anemia are sometimes categorized as these conditions. When bone marrow cells fail to mature into mature blood cells, MDS, also referred to as myelodysplastic syndrome or myelodysplastic syndrome, develops. Instead, these developing blood cells stay in the bone marrow. There are numerous subtypes of MDS., some of which are mild and have a low risk of developing acute myeloid leukemia (AML), while others are more severe. Myelodysplastic syndrome is characterized by abnormal (dysplastic) bone marrow cells that have difficulty producing new blood cells. A large portion of the bone marrow-derived blood cells are deformed. Damaged cells frequently pass away earlier than healthy cells do, and the body also destroys some abnormal blood cells, leaving a person with insufficient healthy blood cells. Although different types of cells can be affected, anemia (the lack of red blood cells) is the most frequent finding in MDS. Acute myeloid leukemia (AML), a myeloid cell cancer with a rapid growth rate, appears in about one-third of MDS patients. Myelodysplastic syndrome was formerly referred to as preleukemia or smoldering leukemia. Because the majority of patients do not go on to develop leukemia, MDS is categorized as a condition with a low malignant potential. MDS is now regarded as a type of cancer because of what medical professionals now know about it.

Anemia in MDS (Myelodysplastic syndromes) (Epidemiology)

Unknown is the true incidence of MDS in the US. Around 1,500 new cases of MDS are reported annually, and the disorder was first recognized as a distinct entity in 1976. Less than 5% of patients with the rash were believed to have the illness at the time. MDS was added to cancer registries for the first time in 2001, despite not being considered a tumor. Incidence estimates for MDS in the US today range widely, from 10,000 to 30,000-55,000 new cases annually. When other hematopoietic conditions are taken into account, the higher number is questioned as possibly being exaggerated. The incidence of MDS appears to be rising. The significant rise is thought to be due to an aging population, though it could also be due to better identification and diagnostic tools. Although MDS can affect anyone, including children, it primarily affects older adults with mild symptoms up to age 70. 86% of MDS. cases were diagnosed in people 60 years of age and older, according to data from the first National Cancer Institute Surveillance and Epidemiology Report (SEER), which covered the period from 2001 to 2003 (median age: 76 years). The incidence of MDS increased significantly with age, from 0 points per 100,000 people at age 40 to 20 points 8 to 36 points per The risk difference between 60 and 80 years is five times greater. Males are more likely than females to develop MDS at any age. The incidence was significantly higher in men than in women (2.7 vs. 2001-2003) according to SEER data from 2010. 40.5% per 100,000). The characteristics of MDS are the same everywhere and it is accessible.

Anemia in MDS (Myelodysplastic syndromes) -Current Market Size & Forecast Trends

The market for anemia associated with myelodysplastic syndromes (MDS) is projected to grow significantly, with estimates indicating a value of approximately USD 2.39 billion in 2022 and expected to reach around USD 5.79 billion by 2032, reflecting a compound annual growth rate (CAGR) of 9.5% during this period. The growth is driven by the increasing incidence of MDS, particularly among the aging population, and the rising demand for effective treatments to manage anemia, which is a common complication in MDS patients. Advancements in therapeutic options, including hypomethylating agents and immunomodulatory drugs, are also contributing to market expansion. North America is expected to dominate the market due to its advanced healthcare infrastructure and significant investments in research and development. Overall, the anemia in MDS market is well-positioned for substantial growth through 2035 as new therapies and improved treatment strategies continue to emerge.

Some MDS patients with low blood counts or bothersome symptoms may not require immediate medical attention. In young, relatively healthy patients, stem cell transplantation (SCT), if a suitable donor is available, may be the treatment of choice for MDS because it is frequently thought to be the only option when treatment is necessary. Unfortunately, a large number of myelodysplastic syndrome patients are elderly or in poor health and may not be candidates for myelodysplastic treatment. MDS is unlikely to be cured if GST is not an option, but it can usually still be treated. The main targets of treatment are symptom relief, side effect avoidance, and complications avoidance. Supportive maintenance therapy (such as blood transfusions or blood cell growth factors) may be beneficial if low blood counts cause issues. Additionally crucial are general medical care and measures to stop and treat infections. Whether or not a person is receiving other MDS treatment, supportive care is crucial. Especially in patients with less severe myelodysplastic syndromes, chemotherapy drugs like azacitidine (Vidaza) or decitabine (Dacogen) are frequently the first option when additional treatment is required. These medications frequently increase blood cell counts, and many patients need fewer blood transfusions and have a better quality of life with less stress as a result. Some people may be able to live longer thanks to these medications. Immune system-suppressing medications like cyclosporine and ATG may also be an option for some people. Lenalidomide (Revlimid) is typically used as the first treatment for people who have del(5q) MDS, a condition in which the cells have lost a portion of chromosome 5. Treatment with azacitidine or decitabine is typically the next step if these medications are ineffective. Some patients with more advanced myelodysplastic syndromes, such as those at higher risk or with worse prognoses or those who appear to be developing acute myeloid leukemia (AML), may be candidates for standard chemotherapy drugs.

Report Highlights

Anemia in MDS (Myelodysplastic syndromes) - Current Market Trends

Anemia in MDS (Myelodysplastic syndromes) - Current & Forecasted Cases across the G8 Countries

Anemia in MDS (Myelodysplastic syndromes) - Market Opportunities and Sales Potential for Agents

Anemia in MDS (Myelodysplastic syndromes) - Patient-based Market Forecast to 2035

Anemia in MDS (Myelodysplastic syndromes) - Untapped Business Opportunities

Anemia in MDS (Myelodysplastic syndromes) - Product Positioning Vis-a-vis Competitors' Products

Anemia in MDS (Myelodysplastic syndromes) - KOLs Insight